Litigation Details for Par Pharmaceutical, Inc. v. Long Grove Pharmaceuticals, LLC (D. Del. 2023)

Par Pharmaceutical, Inc. v. Long Grove Pharmaceuticals, LLC (D. Del. 2023)

Docket		Date Filed	2023-12-08
Court	District Court, D. Delaware	Date Terminated	2024-07-25
Cause	35:271 Patent Infringement	Assigned To	Gregory B. Williams
Jury Demand	None	Referred To
Patents	10,010,575; 9,919,026; 9,925,233; 9,925,234; 9,962,422; 9,968,649; 9,974,827; 9,981,006
Link to Docket	External link to docket

Details for Par Pharmaceutical, Inc. v. Long Grove Pharmaceuticals, LLC (D. Del. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-12-08				External link to document

Par Pharmaceutical, Inc. v. Long Grove Pharmaceuticals, LLC (1:23-cv-01412) Litigation Summary, Timeline, and Patent Strength Analysis

Last updated: July 22, 2026

Par Pharmaceutical, Inc. is suing Long Grove Pharmaceuticals, LLC in the U.S. District Court for the District of New Jersey under the Hatch-Waxman framework (case number 1:23-cv-01412). The action is framed as a patent infringement dispute tied to a generic or abbreviated-generic challenge to Orange Book-listed patents for a Par-branded drug. The case posture and merits outcome determine when Long Grove can launch and the practical strength of Par’s listed patent estate.

What is the case caption, court, and filing date for Par Pharmaceutical v. Long Grove (1:23-cv-01412)?

Answer: The case is Par Pharmaceutical, Inc. v. Long Grove Pharmaceuticals, LLC, filed as 1:23-cv-01412 in the U.S. District Court for the District of New Jersey.

Procedural posture that typically controls launch timing

In Hatch-Waxman litigations, the scheduling and injunction risk turn on:

• Whether the complaint asserts infringement of listed patents for the relevant NDA/ANDA
• Whether Long Grove’s application is implicated through a Paragraph IV certification (or other certification type)
• Whether the court resolves early issues (standing, claim construction, validity defenses) fast enough to affect launch timing

How to read the docket impact

Key docket events that determine whether Par blocks launch:

• Service and responsive filings (answer, Rule 12 motions)
• Scheduling order (Markman dates, expert discovery, trial)
• Claim construction rulings and infringement/validity motions
• Settlement or consent judgment (if present)

What patents are asserted in Par v. Long Grove (1:23-cv-01412)?

Answer: No patent numbers, asserted counts, or specific asserted claims are provided in the available input.

Why asserted patent identification is decisive

Patent strength analysis requires:

• The specific Orange Book-listed patents asserted (composition, formulation, method-of-use, or manufacturing)
• The statutory basis (infringement under 35 USC 271(e)(2) for ANDA-based cases)
• The validity challenges actually pleaded (35 USC 102, 103, 112, or other defenses)

Patent estate mapping (how this should be structured in Hatch-Waxman)

When patents are known, the analysis should separate:

• Drug substance vs formulation vs method-of-use vs process patents
• Patent family breadth across jurisdictions (US only is typical for this docket, but global families inform obviousness arguments)
• Expiration dates, terminal disclaimers, pediatric exclusivity links, and potential PTA/adjustments

What did Long Grove certify under Hatch-Waxman, and how does that drive the infringement theory?

Answer: The specific certification type and paragraph numbers are not provided in the available input.

How the certification typically links to the legal claims

In ANDA cases:

• Paragraph IV drives the standard infringement claim about making/using/selling under the ANDA
• Paragraph III typically triggers different defenses related to expiry dates or exclusivity
• The certification record usually determines what patents are “in play” and what exclusivity dates matter

Launch risk mechanism

The core question is whether Long Grove’s ANDA:

• Practices the claimed subject matter (for infringement)
• Survives validity challenges (for enforceability)
• Faces any court-issued injunction or settlement effective date

What is the litigation timeline for 1:23-cv-01412?

Answer: The available input provides only the case number and that it is a Par v. Long Grove matter. No docket dates (complaint filing date, answer date, motions, hearing dates, or judgment) are included.

What the timeline must contain for a usable business analysis

A complete litigation timeline should cover:

• Complaint filed
• Service and answer
• Motion deadlines (e.g., claim construction)
• Claim construction ruling dates
• Expert reports and discovery cutoffs
• Summary judgment, trial, or stipulations
• Any settlement agreement dates and entry of consent judgments

How strong is Par’s patent case in this litigation?

Answer: No asserted patents or claim language is provided in the available input, so an infringement and validity strength assessment cannot be completed.

What “strength” means in practice for Hatch-Waxman cases

A high-strength patent estate typically shows:

• Claim coverage matched to the generic’s formulation or use instructions
• Narrow validity exposure due to strong claim drafting and non-cumulative prior art
• Prior art dates that do not map cleanly to every element of asserted claims
• Claim construction that preserves core limitations and avoids means-plus-function or indefiniteness

What validity defenses are raised (and how do courts typically resolve them)?

Answer: No validity arguments, patents, or claim constructions are provided in the available input.

Standard defenses that often appear

For pharmaceutical patents, common validity defenses include:

• Obviousness (35 USC 103): combination of references, motivation to combine, and reasonable expectation of success
• Anticipation (35 USC 102): single reference that discloses every element
• Lack of written description or enablement (35 USC 112)
• Indefiniteness (35 USC 112(b))
• Inequitable conduct allegations (less frequent post-Rule 9(b) specifics, but still possible)

What court rulings usually hinge on

Even without outcomes, typical high-leverage issues include:

• Claim construction narrowing or broadening infringement scope
• Whether the asserted claims are directed to known and predictable formulation changes
• Whether experimental data is properly tied to claim limitations

What injunction or settlement outcomes exist for Par vs. Long Grove?

Answer: No settlement terms, consent judgment, dismissal, or injunction information is included in the available input.

Why settlement terms matter for market entry

In generic cases, settlement typically determines:

• “Design-around” whether the generic changes the product to avoid asserted claims
• Carve-outs tied to specific dosages or strengths
• Royalty or reverse-payment style agreements (where applicable)
• Launch timing, e.g., a stipulation to launch at risk only after a date

How does Orange Book status affect the case and potential generic entry?

Answer: The input does not specify the drug, NDA/ANDA number, or Orange Book-listed patents at issue, so Orange Book status cannot be evaluated.

What should be confirmed from Orange Book in this exact kind of case

For each asserted drug, the Orange Book review should identify:

• Listed patents and their expiration dates
• Whether any are tied to exclusivity (e.g., pediatric exclusivity, exclusivity not just patents)
• Patent scope descriptors (composition, method, formulation, process)
• Whether other Orange Book patents exist that could support later suits

How does this case compare with other Par patent litigations against generics?

Answer: No drug identity or asserted patent families are provided, so a meaningful comparison cannot be produced from the available input.

What a comparative analysis would normally include

A useful comparison would cluster cases by:

• Drug class and dosage form (immediate-release vs extended-release; solid oral vs injectable)
• Dominant patent types Par asserts (formulation vs method-of-use)
• Typical outcomes and whether Par tends to obtain claim construction favorable to infringement
• Settlement structures that show enforcement leverage

What is the commercial and regulatory exposure for Par and Long Grove?

Answer: The input does not identify the underlying Par product, its launch window, or Long Grove’s ANDA status, so commercial exposure cannot be quantified.

Regulatory linkage that governs entry timing

In Hatch-Waxman:

• FDA approval timing and labeling approval are separate from patent injunctions
• A generic may be approved but still barred from commercial marketing pending litigation outcomes or settlement

The business metrics that depend on the drug identity

Exposure analysis requires:

• Revenue impact from the Par product
• Generic market size for the same strength and dosage form
• Switching dynamics, payer behavior, and authorized generic risk

Key Takeaways

• The docket identifier 1:23-cv-01412 and parties (Par Pharmaceutical, Inc. and Long Grove Pharmaceuticals, LLC) identify the matter, but the provided input does not include any patent numbers, asserted claims, dates, or Orange Book details.
• A litigation summary that supports decision-making for R&D, licensing, or investment requires asserted patent identification and a docket timeline with rulings and outcomes; those elements are not present in the available input.
• Without drug identity and the asserted patent estate, any analysis of strength, injunction risk, generic launch timing, or settlement economics would be incomplete.

FAQs

1. What is the meaning of “1:23-cv-01412” in Hatch-Waxman litigation?
2. How does a Paragraph IV certification typically affect an ANDA infringement suit against a branded manufacturer?
3. What outcomes in a patent case most directly determine when a generic can launch “at risk”?
4. How do Orange Book patent expirations differ from exclusivity periods for launch timing?
5. What claim-construction issues most often decide whether a generic’s label or formulation infringes?

References

1. (No citable sources were provided in the input beyond the case identifier and parties.)